
No results matched your search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ORPHA | Copenhagen | DKK | Delayed | |
ORPH | NASDAQ | USD | Real-time | |
1TB | Frankfurt | EUR | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Sell | Sell | Buy | Buy |
Technical Indicators | Neutral | Neutral | BUY | BUY | Strong Buy |
Summary | Neutral | Neutral | Neutral | Buy | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bullish | 1H | Current | |||
Completed Patterns | |||||
Tri-Star Bearish | 30 | 1 | Mar 04, 2021 21:30 | ||
Tri-Star Bearish | 15 | 1 | Mar 04, 2021 21:45 | ||
Tri-Star Bullish | 1H | 2 | Mar 04, 2021 17:00 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Copenhagen | 76.80 | 0.00 | 0.00 | 84,468 | -2.78% | DKK | 05/03 | ||
NASDAQ | 12.60 | 0.00 | 0.00 | 3,708 | +1.27% | USD | 05/03 | ||
Frankfurt | 10.400 | 0.000 | 0.000 | 0 | +1.17% | EUR | 05/03 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Zenith Bank | 25.30 | 25.40 | 24.95 | 0.00 | 0.00% | 46.85M | 05/03 | ||
FBN Holdings | 7.10 | 7.10 | 6.85 | +0.05 | +0.71% | 26.50M | 05/03 | ||
Guaranty Trust Bank | 31.20 | 31.05 | 30.90 | -0.50 | -1.59% | 20.83M | 05/03 | ||
UBA | 7.95 | 7.95 | 7.85 | 0.00 | 0.00% | 23.30M | 05/03 | ||
MTN Nigeria | 160.20 | 160.20 | 160.20 | -9.80 | -5.76% | 643.20K | 05/03 | ||
Oando Plc | 2.65 | 3.00 | 2.65 | -0.25 | -8.62% | 4.05M | 05/03 | ||
Access Bank | 7.90 | 7.85 | 7.70 | +0.10 | +1.28% | 10.47M | 05/03 | ||
Fidson | 4.650 | 4.650 | 4.650 | +0.240 | +5.44% | 162.29K | 05/03 | ||
Japaul Gold Ventures | 0.51 | 0.50 | 0.48 | -0.04 | -7.55% | 12.46M | 05/03 | ||
Julius Berger | 18.70 | 18.80 | 18.80 | +0.10 | +0.53% | 329.30K | 05/03 |
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review